Why the study?
Does dipyridamole-echocardiography compared to dipyridamole-thallium scintigraphy improve diagnostic accuracy for myocardial ischemia in patients with suspected coronary artery disease?
Does dipyridamole-echocardiography compared to dipyridamole-thallium scintigraphy improve diagnostic accuracy for myocardial ischemia in patients with suspected coronary artery disease?
Dipyridamole-thallium scintigraphy provides higher sensitivity but lower specificity compared to dipyridamole-echocardiography for the detection of coronary artery disease.
Scintigraphy may aid sensitivity-driven detection in suspected CAD; leaves open optimal test selection pending randomized data.
After an intravenous infusion of dipyridamole (0.56 mg/kg), we performed both echocardiography and thallium scintigraphy in 63 patients who were referred for known or suspected coronary artery disease. Of those patients, 25 returned for coronary arteriography within 1 month after the tests, thus forming the study group for this report. Sensitivity for detection of coronary artery disease, when analyzed region-by-region, was 80% for thallium scintigraphy and 57% for echocardiography, whereas specificity was 85% and 98%, respectively. When evaluating individual patients for the presence or absence of ischemia, we found a sensitivity of 95% for scintigraphy and 58% for echocardiography; corresponding specificities were 50% and 100%. By using arteriography as the gold standard for comparison, it appears that thallium scintigraphy has a significantly higher sensitivity but lower specificity for the detection of coronary artery disease than does echocardiography. Echocardiography may, however, be a useful adjunct to thallium scintigraphy in the evaluation of patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Perin et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: